Legal Opinion
Lorazepam & Clorazepate Antitrust Litigation v. Mylan Laboratories, Inc.
District Court, District of Columbia
Decided July 2, 2001No. MDL 1290(TFH); MISC. 99MS276(TFH), CIV. 99-0790(TFH)PublishedCited by 64 opinions
1Opinion of the Court
MEMORANDUM OPINION
HOGAN, Chief Judge.
Pending before the Court are the plaintiffs’ motion for class certification and the defendants’ motion to dismiss in this MDL antitrust action. The putative direct purchaser plaintiffs claim that as a result of the defendants’ anticompetitive behavior — specifically, the defendants’ conspiracy to monopolize, monopolization, and price fixing concerning certain generic anti-anxiety drugs — they paid enormously higher prices than they would have paid in a competitive market. En route to their ultimate goal of treble-damages under the Clayton Act for the…
2Cases cited58 opinions
- Amchem Products, Inc. v. WindsorSupreme Court of the United States · 1997
- Eisen v. Carlisle & JacquelinSupreme Court of the United States · 1974
- Illinois Brick Co. v. IllinoisSupreme Court of the United States · 1977
- Hanover Shoe, Inc. v. United Shoe MacHinery Corp.Supreme Court of the United States · 1968
- Blackie v. BarrackCourt of Appeals for the Ninth Circuit · 1975
53 more not listed; retrieve them via the Exa API.
3Cited by64 opinions
- In Re Lorazepam & Clorazepate Antitrust LitigationCourt of Appeals for the D.C. Circuit · 2002
- Livengood Feeds, Inc. v. KgaaDistrict Court, District of Columbia · 2002
- In re Pharmaceutical Industry Average Wholesale Price LitigationDistrict Court, D. Massachusetts · 2005
- Federal Trade Commission v. Mylan Laboratories, Inc.District Court, District of Columbia · 2002
- In re Relafen Antitrust LitigationDistrict Court, D. Massachusetts · 2004
59 more not listed; retrieve them via the Exa API.